Daniel Gozzi, MD
Endocrinology, Diabetes & Metabolism · Suitland, MDNPI 1316931413
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $912,764 of the $1,186,950 with a category attached, or 76.9%. 60 manufacturers reported payments, led by Lilly USA, LLC at 44.9% of the total. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,366 payments — averaging $501.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$533K
- Novo Nordisk$358K
- Sanofi-aventis U.S. LLC$217K
- AstraZeneca$30K
- AbbVie$22K
- Boehringer Ingelheim$10K
- plus $18K from 54 others
Across 15 payments — averaging $2200.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$33K
What the payments were for
- Consulting fees$9,2251%
- Speaking & faculty fees$912,76477%
- Travel & lodging$222,35019%
- Food & beverage$42,5364%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$307,437
- TZIELD$186,337
- Ozempic$174,188
- RYBELSUS$135,737
- TRULICITY$79,071
- JARDIANCE$35,030
- FARXIGA$27,323
- SOLIQUA 100/33$21,594
- HUMULIN$18,346
- Tresiba$16,471
- Synthroid$15,195
- Xultophy 100/3.6$10,354
- TOUJEO$6,861
- AFREZZA$3,776
- CeQur Simplicity$1,001
- UNITHROID$500
- RECORLEV$488
- Wegovy$127
- REZDIFFRA$126
- Pogo Automatic Blood Glucose Monitoring System$105
How this compares
$1,186,950 in reported general payments places this provider in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 332 | $653,893 |
| MounjaroTirzepatide | 326 | $386,933 |
| TrulicityDulaglutide | 106 | $207,507 |
| Tresiba Flextouch U-200Insulin Degludec | 148 | $203,684 |
| FarxigaDapagliflozin Propanediol | 80 | $99,559 |
| JardianceEmpagliflozin | 71 | $96,920 |
| RybelsusSemaglutide | 60 | $84,397 |
| Xigduo XrDapaglifloz Propaned/Metformin | 39 | $46,508 |
| JanuviaSitagliptin Phosphate | 36 | $46,224 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $35,584 |
| Tresiba Flextouch U-100Insulin Degludec | 49 | $33,409 |
| ProliaDenosumab | 19 | $32,561 |
| SynthroidLevothyroxine Sodium | 270 | $27,644 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $26,540 |
| TradjentaLinagliptin | 23 | $26,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $357,830 | $745,324408 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $532,510 | $595,013448 claims |
| Boehringer IngelheimJardiance, Tradjenta | $10,337 | $122,96194 claims |
| AstraZenecaFarxiga | $29,557 | $99,55980 claims |
| MerckJanuvia, Janumet Xr | $166 | $66,39051 claims |
| AmgenProlia | $558 | $32,56119 claims |
| AbbVieSynthroid | $21,711 | $27,644270 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $1,856 | $7,155332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Suitland
- Osvaldo GonzalezSuitland$31K
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.